What is the appropriate dosing of amoxicillin‑clavulanate (Amoxiclav) for an adult with a skin or soft‑tissue infection, including oral and intravenous regimens and adjustments for renal impairment or severe β‑lactam allergy?

Amoxicillin-Clavulanate Dosing for Adult Skin and Soft-Tissue Infections

For adult skin and soft-tissue infections, use oral amoxicillin-clavulanate 875/125 mg twice daily, or intravenous ampicillin-sulbactam 1.5–3.0 g every 6–8 hours for severe infections; avoid the 875 mg dose in patients with GFR <30 mL/min, and use alternative agents (doxycycline, fluoroquinolones, or clindamycin combinations) in patients with severe β-lactam allergy.

Oral Dosing for Outpatient Management

For mild to moderate skin and soft-tissue infections requiring aerobic and anaerobic coverage (particularly animal or human bites):

• Standard dose: Amoxicillin-clavulanate 875/125 mg twice daily 1, 2
• Duration: 7–10 days for most infections 1
• Administration: Take at the start of meals to enhance clavulanate absorption and minimize gastrointestinal side effects 2

The twice-daily formulation provides equivalent efficacy to three-times-daily dosing with improved tolerability due to reduced daily clavulanate exposure 3. This is the guideline-recommended first-line oral agent for bite wounds requiring mixed aerobic-anaerobic coverage 1.

Intravenous Dosing for Severe Infections

For hospitalized patients or severe infections:

• Ampicillin-sulbactam: 1.5–3.0 g every 6–8 hours IV 1
• This provides equivalent β-lactam/β-lactamase inhibitor coverage when oral therapy is inappropriate

Important limitation: Both amoxicillin-clavulanate and ampicillin-sulbactam miss MRSA coverage 1. For severe infections with systemic signs (SIRS) or risk factors for MRSA (injection drug use, nasal colonization, penetrating trauma), add vancomycin or another anti-MRSA agent 1.

Renal Dose Adjustments

Critical dosing modification 2:

• GFR <30 mL/min: Do NOT use the 875 mg tablet formulation
• Patients with severe renal impairment require dose reduction, though specific alternative dosing is not provided in the FDA label
• In critically ill patients on renal replacement therapy, clearance is significantly affected—consider higher doses (2.2 g every 6–8 hours) with therapeutic drug monitoring 4

Standard dosing is appropriate for mild-to-moderate renal impairment (GFR ≥30 mL/min) 2.

Management of β-Lactam Allergy

For patients with severe β-lactam allergy (anaphylaxis, severe cutaneous reactions), amoxicillin-clavulanate is contraindicated. Alternative regimens for bite wounds include 1:

Oral alternatives:

• Doxycycline 100 mg twice daily PLUS metronidazole 250–500 mg three times daily (covers aerobes and anaerobes separately)
• Moxifloxacin 400 mg daily (monotherapy with anaerobic coverage)
• Levofloxacin 750 mg daily (though weaker anaerobic coverage)

IV alternatives for severe infections:

• Fluoroquinolone (ciprofloxacin 400 mg IV every 12 hours or levofloxacin 750 mg IV daily) PLUS metronidazole 500 mg IV every 8 hours

Allergy Considerations

Recent data show that clavulanate itself is a major allergen, responsible for over one-third of immediate allergic reactions attributed to amoxicillin-clavulanate 5. In patients with documented clavulanate-selective allergy:

• Pure β-lactams (penicillin, amoxicillin, cephalosporins) may be tolerated
• Formal allergology workup can identify selective clavulanate reactors who can safely receive other β-lactams

Clinical Context and Pitfalls

When amoxicillin-clavulanate is appropriate:

• Animal bites (dog, cat) requiring Pasteurella multocida coverage 1
• Human bites requiring oral anaerobe coverage 1
• Mild cellulitis when MSSA coverage is desired alongside streptococcal coverage

When to avoid or add coverage:

• MRSA risk factors: Add vancomycin, linezolid, or daptomycin 1, 6
• Severe necrotizing infections: Use broader regimens (piperacillin-tazobactam or carbapenems plus vancomycin) 1
• Gram-negative concerns: Some gram-negative rods are resistant; consider alternatives 1

Gastrointestinal tolerability: Amoxicillin-clavulanate causes significantly higher GI side effects (34%) compared to alternatives like cefaclor (3%) 7, though most patients tolerate completion of therapy. Taking with food reduces this risk 2.

The combination has been a "community workhorse" for 40 years 8, but rising ESBL prevalence limits empirical use for certain infections. For skin and soft-tissue infections specifically, its role remains well-established when appropriate pathogen coverage is needed 1, 9.